Advertisement

Topics

Refractory Leukemia - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Refractory Leukemia - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 41-page report is available in PDF from $2000.

Refractory Leukemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Refractory Leukemia - Pipeline Review, H1 2015’, provides an overview of the Refractory Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Refractory Leukemia Overview 6
Therapeutics Development 7
Pipeline Products for Refractory Leukemia - Overview 7
Pipeline Products for Refractory Leukemia - Comparative Analysis 8
Refractory Leukemia - Therapeutics under Development by Companies 9
Refractory Leukemia - Pipeline Products Glance 10
Clinical Stage Products 10
Refractory Leukemia - Products under Development by Companies 11
Refractory Leukemia - Companies Involved in Therapeutics Development 12
Bayer AG 12
Colby Pharmaceutical Company 13
Galileo Research s.r.l. 14
Novartis AG 15
XBiotech USA, Inc. 16
Refractory Leukemia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BAY-1143572 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CA-18C3 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
JVRS-100 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TALL-104 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
trametinib dimethyl sulfoxide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Refractory Leukemia - Recent Pipeline Updates 35
Refractory Leukemia - Dormant Projects 38
Refractory Leukemia - Dormant Projects 38
Refractory Leukemia - Discontinued Products 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

For more information open Refractory Leukemia - Pipeline Review, H1 2015.

SKU: GMDHC6797IDB

Original Article: Refractory Leukemia - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Refractory Leukemia - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...